Sustained seroconversion of chronic hepatitis B infection after stem cell transplantation.
We present an 18-yr-old adolescent with acute lymphocytic leukemia, who underwent peripheral blood SCT with serologically and histologically documented chronic hepatitis B infection. Prior and during the transplant process, lamivudine was administered orally and he underwent SCT with a twofold decrease in viral load at the time of transplant from his HLA full matched, HBV natural immune (anti-HBs and anti-HBc positive) donor. Successful engraftment was achieved and three months after SCT, HBV seroconversion was documented accompanied with an ALT flare. Chronic graft-versus-host disease coincided after the transplantation, and he has been on immunosuppressive treatment for 25 months with sustained HBV seroconversion. We assume that adoptive immunity transfer combined with antiviral treatment might also constitute sustained seroconversion in chronic HBV, besides the reported risk of reactivation.
Serap
Aksoylar
A
Ege University, Pediatric Oncology and Bone Marrow Transplantation Unit Ege University, Pediatric Gastroenterology, Hepatology and Nutrition, Izmir, Turkey.
Funda
Ozgenc
O
Bengu
Kadioglu
K
Mehmet
Kantar
K
Nazan
Cetingul
C
Rasit
Yagci
Y
Savas
Kansoy
K
D056704:Adaptive Immunity; D000293:Adolescent; D006086:Graft vs Host Disease; D006515:Hepatitis B virus / Q000235:genetics; D019694:Hepatitis B, Chronic / Q000150:complications* / Q000821:virology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods; D019259:Lamivudine / Q000627:therapeutic use; D008297:Male; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000150:complications* / Q000628:therapy*; D012306:Risk; D033581:Stem Cell Transplantation / Q000379:methods*; D016896:Treatment Outcome; D019562:Viral Load
D007166:Immunosuppressive Agents; D019259:Lamivudine